These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 26546940)

  • 21. A national survey on hospital formulary management processes.
    Anagnostis E; Wordell C; Guharoy R; Beckett R; Price V
    J Pharm Pract; 2011 Aug; 24(4):409-16. PubMed ID: 21768310
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Off-label use in oncology: an inexhaustible topic?!].
    Weissbach L; Riese J
    Urologe A; 2006 Nov; 45(11):1410, 1412-4. PubMed ID: 17043888
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Off-label prescriptions in Italian hospices: a national survey.
    Toscani F; Di Giulio P; Campi R; Pellerin I; De Luca A; Casale G;
    J Pain Symptom Manage; 2009 Sep; 38(3):365-71. PubMed ID: 19564095
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Off-label use of anti-cancer drugs between clinical practice and research: the Italian experience.
    Lerose R; Musto P; Aieta M; Papa C; Tartarone A
    Eur J Clin Pharmacol; 2012 May; 68(5):505-12. PubMed ID: 22166932
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Off-label prescriptions: how to identify them, frame them, announce them and monitor them in practice?
    Le Jeunne C; Billon N; Dandon A; ; Berdaï D; Adgibi Y; Bergmann JF; Bordet R; Carpentier A; Cohn E; Courcier S; Girault D; Goni S; Jolliet P; Liard F; Prot-Labarthe S; Simon T; Vernotte C; Westerloppe J
    Therapie; 2013; 68(4):225-39. PubMed ID: 23981260
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A survey of off-label prescribing for inpatients with mild intellectual disability and mental illness.
    Haw C; Stubbs J
    J Intellect Disabil Res; 2005 Nov; 49(Pt 11):858-64. PubMed ID: 16207284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Off-label antidepressant use in children and adolescents compared with young adults: extent and level of evidence.
    Czaja AS; Valuck R
    Pharmacoepidemiol Drug Saf; 2012 Sep; 21(9):997-1004. PubMed ID: 22760843
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Addressing innovative off-label medication use at an academic medical center.
    Skledar SJ; Corman SL; Smitherman T
    Am J Health Syst Pharm; 2015 Mar; 72(6):469-77. PubMed ID: 25736942
    [TBL] [Abstract][Full Text] [Related]  

  • 29. When is off-label off-road?
    de Vries EGE; Cherny NI; Voest EE
    Ann Oncol; 2019 Oct; 30(10):1536-1538. PubMed ID: 31688929
    [No Abstract]   [Full Text] [Related]  

  • 30. Hospital management of outpatient oncology treatment decisions: a survey to identify strategies and concerns.
    Li E; Schleif R; Edelen B
    J Oncol Pract; 2013 Sep; 9(5):e248-54. PubMed ID: 23943887
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project.
    Herbrand AK; Schmitt AM; Briel M; Diem S; Ewald H; Hoogkamer A; Joerger M; Mc Cord KA; Novak U; Sricharoenchai S; Hemkens LG; Kasenda B
    ESMO Open; 2019; 4(6):e000596. PubMed ID: 31803503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists.
    Conti RM; Bernstein AC; Villaflor VM; Schilsky RL; Rosenthal MB; Bach PB
    J Clin Oncol; 2013 Mar; 31(9):1134-9. PubMed ID: 23423747
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Off-label drug use in children should be rational.
    Bonati M; Pandolfini C
    Arch Dis Child; 2011 Sep; 96(9):870-1. PubMed ID: 21715392
    [No Abstract]   [Full Text] [Related]  

  • 34. [Cancer: Is it really so different? Particularities of oncologic drugs from the perspective of the pharmaceutical regulatory agency].
    Enzmann H; Broich K
    Z Evid Fortbild Qual Gesundhwes; 2013; 107(2):120-8. PubMed ID: 23663906
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Off-label drug use in hospitals].
    Danés I; Alerany C; Ferrer A; Vallano A
    Med Clin (Barc); 2014 Oct; 143(7):327-8. PubMed ID: 24183116
    [No Abstract]   [Full Text] [Related]  

  • 36. Paediatric Oncology at the Crossroads: A Call for Change.
    Rose K
    Pharmaceut Med; 2020 Oct; 34(5):297-300. PubMed ID: 33026589
    [No Abstract]   [Full Text] [Related]  

  • 37. Unlicensed and off-label drug use in an Irish neonatal intensive care unit: a prospective cohort study.
    Kieran EA; O'Callaghan N; O'Donnell CP
    Acta Paediatr; 2014 Apr; 103(4):e139-42. PubMed ID: 24397831
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes of off-label drug uses in hospitals: a multicentric prospective study.
    Danés I; Agustí A; Vallano A; Alerany C; Martínez J; Bosch JA; Ferrer A; Gratacós L; Pérez A; Olmo M; Marron SM; Valderrama A; Bonafont X
    Eur J Clin Pharmacol; 2014 Nov; 70(11):1385-93. PubMed ID: 25196202
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Off-label use of misoprostol for labor induction in Germany: a national survey.
    Voigt F; Goecke TW; Najjari L; Pecks U; Maass N; Rath W
    Eur J Obstet Gynecol Reprod Biol; 2015 Apr; 187():85-9. PubMed ID: 25553610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recommendations for clinical trials of off-label drugs used to treat advanced-stage cancer.
    Mullins CD; Montgomery R; Abernethy AP; Hussain A; Pearson SD; Tunis S;
    J Clin Oncol; 2012 Feb; 30(6):661-6. PubMed ID: 22253467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.